MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices, following a significant drop in the company's stock price after a trial report [1][2]. Investigation Details - The investigation focuses on whether MoonLake has engaged in unlawful business practices that may have led to investor losses [1][2]. - The firm is encouraging investors who suffered losses to contact them for discussions regarding their legal rights [1][3]. Stock Performance - On September 29, 2025, MoonLake Immunotherapeutics reported that its VELA-2 trial did not achieve statistical significance due to unexpected results in the placebo group, leading to a drastic stock decline of 89.9% on the same day [6].